AXN 027
Alternative Names: AXN-027Latest Information Update: 18 Sep 2024
Price :
$50 *
At a glance
- Originator AXONIS Therapeutics
- Class Analgesics; Antiepileptic drugs; Small molecules
- Mechanism of Action K Cl-cotransporter agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Epilepsy; Neuropathic pain; Spinal cord injuries
Most Recent Events
- 27 Aug 2024 Preclinical trials in Epilepsy in USA (PO) prior to August 2024 (AXONIS therapeutics pipeline, August 2024)
- 27 Aug 2024 Preclinical trials in Neuropathic pain in USA (PO) prior to August 2024 (AXONIS therapeutics pipeline, August 2024)
- 27 Aug 2024 Preclinical trials in Spinal cord injuries in USA (PO) prior to August 2024 (AXONIS therapeutics pipeline, August 2024)